Scientific Background
PreSENTIA hereditary Prostate cancer panel tests for numerous germline mutations that could cause prostate cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary prostate cancers are those that have:
- • Several first degree family members with prostate cancer
- • Family members diagnosed with prostate cancer at a young age
- • Family members diagnosed with other cancer types, including breast, ovarian, and pancreatic
- • Multiple cancers in the same family member
- • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- • Personal history of previous malignancies
How many genes are tested in this panel?
15 genes
How many hereditary cancer syndromes are associated with this panel?
6 Hereditary cancer syndromes are associated with this panel. These are:
• Ataxia-telangiectasia syndrome (ATM)
- • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- • Li-Fraumeni syndrome (TP53)
- • Li-Fraumeni syndrome 2 (CHEK2)
- • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)• PTEN hamartoma syndrome (PTEN)